Lupin takes 82.2% stake in Kaveri Therapeutics, licences 2 oncology assets for $1.6mn
LI has received 332,000 common shares in Kaveri, which will advance the oncology programme through global clinical trials
· 7/21/2026, 10:03:46 AM· 2 min read
LI has received 332,000 common shares in Kaveri, which will advance the oncology programme through global clinical trials
Read original story →
